Age-specific vaccine effectiveness of seasonal 2010/2011 and pandemic influenza A(H1N1) 2009 vaccines in preventing influenza in the United Kingdom

R.G. Pebody; Nick Andrews; D.M. Fleming; J. McMenamin; S. Cottrell; B. Smyth; H. Durnall; Chris Robertson; W. Carman; J. Ellis; P. Sebastian-Pillai; Maria Zambon; C. Hearns; C. Moore; D.R. Thomas; J.M. Watson

doi:10.1017/S0950268812001148

Age-specific vaccine effectiveness of seasonal 2010/2011 and pandemic influenza A(H1N1) 2009 vaccines in preventing influenza in the United Kingdom

R.G. Pebody, Nick Andrews, D.M. Fleming, J. McMenamin, S. Cottrell, B. Smyth, H. Durnall, Chris Robertson, W. Carman, J. Ellis, P. Sebastian-Pillai, Maria Zambon, C. Hearns, C. Moore, D.R. Thomas, J.M. Watson

Mathematics And Statistics

Research output: Contribution to journal › Article › peer-review

32 Citations (Scopus)

161 Downloads (Pure)

Abstract

An analysis was undertaken to measure age-specific vaccine effectiveness (VE) of 2010/11 trivalent seasonal influenza vaccine (TIV) and monovalent 2009 pandemic influenza vaccine (PIV) administered in 2009/2010. The test-negative case-control study design was employed based on patients consulting primary care. Overall TIV effectiveness, adjusted for age and month, against confirmed influenza A(H1N1)pdm 2009 infection was 56% (95% CI 42–66); age-specific
adjusted VE was 87% (95% CI 45–97) in <5-year-olds and 84% (95% CI 27–97) in 5- to 14-year-olds. Adjusted VE for PIV was only 28% (95% CI x6 to 51) overall and 72% (95% CI 15–91) in <5-year-olds. For confirmed influenza B infection, TIV effectiveness was 57% (95% CI 42–68) and in 5- to 14-year-olds 75% (95% CI 32–91). TIV provided moderate protection against the main circulating strains in 2010/2011, with higher protection in children. PIV administered during the previous season provided residual protection after 1 year, particularly in the <5 years age group.

Original language	English
Pages (from-to)	620-630
Number of pages	11
Journal	Epidemiology and Infection
Volume	141
Issue number	3
Early online date	13 Jun 2012
DOIs	https://doi.org/10.1017/S0950268812001148
Publication status	Published - Mar 2013

Keywords

Influenza
vaccine-preventable diseases
influenza vaccines
age-specific
vaccine effectiveness
pandemic

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1017/S0950268812001148

Age specificSubmitted manuscript, 160 KB

Cite this

Pebody, R. G., Andrews, N., Fleming, D. M., McMenamin, J., Cottrell, S., Smyth, B., Durnall, H., Robertson, C., Carman, W., Ellis, J., Sebastian-Pillai, P., Zambon, M., Hearns, C., Moore, C., Thomas, D. R., & Watson, J. M. (2013). Age-specific vaccine effectiveness of seasonal 2010/2011 and pandemic influenza A(H1N1) 2009 vaccines in preventing influenza in the United Kingdom. Epidemiology and Infection, 141(3), 620-630. https://doi.org/10.1017/S0950268812001148

@article{51eae92727be4362bd00f2f8bd0bcfe1,

title = "Age-specific vaccine effectiveness of seasonal 2010/2011 and pandemic influenza A(H1N1) 2009 vaccines in preventing influenza in the United Kingdom",

abstract = "An analysis was undertaken to measure age-specific vaccine effectiveness (VE) of 2010/11 trivalent seasonal influenza vaccine (TIV) and monovalent 2009 pandemic influenza vaccine (PIV) administered in 2009/2010. The test-negative case-control study design was employed based on patients consulting primary care. Overall TIV effectiveness, adjusted for age and month, against confirmed influenza A(H1N1)pdm 2009 infection was 56% (95% CI 42–66); age-specificadjusted VE was 87% (95% CI 45–97) in <5-year-olds and 84% (95% CI 27–97) in 5- to 14-year-olds. Adjusted VE for PIV was only 28% (95% CI x6 to 51) overall and 72% (95% CI 15–91) in <5-year-olds. For confirmed influenza B infection, TIV effectiveness was 57% (95% CI 42–68) and in 5- to 14-year-olds 75% (95% CI 32–91). TIV provided moderate protection against the main circulating strains in 2010/2011, with higher protection in children. PIV administered during the previous season provided residual protection after 1 year, particularly in the <5 years age group. ",

keywords = "Influenza, vaccine-preventable diseases, influenza vaccines, age-specific, vaccine effectiveness , pandemic",

author = "R.G. Pebody and Nick Andrews and D.M. Fleming and J. McMenamin and S. Cottrell and B. Smyth and H. Durnall and Chris Robertson and W. Carman and J. Ellis and P. Sebastian-Pillai and Maria Zambon and C. Hearns and C. Moore and D.R. Thomas and J.M. Watson",

year = "2013",

month = mar,

doi = "10.1017/S0950268812001148",

language = "English",

volume = "141",

pages = "620--630",

journal = "Epidemiology and Infection",

issn = "0950-2688",

publisher = "Cambridge University Press",

number = "3",

}

Pebody, RG, Andrews, N, Fleming, DM, McMenamin, J, Cottrell, S, Smyth, B, Durnall, H, Robertson, C, Carman, W, Ellis, J, Sebastian-Pillai, P, Zambon, M, Hearns, C, Moore, C, Thomas, DR & Watson, JM 2013, 'Age-specific vaccine effectiveness of seasonal 2010/2011 and pandemic influenza A(H1N1) 2009 vaccines in preventing influenza in the United Kingdom', Epidemiology and Infection, vol. 141, no. 3, pp. 620-630. https://doi.org/10.1017/S0950268812001148

TY - JOUR

T1 - Age-specific vaccine effectiveness of seasonal 2010/2011 and pandemic influenza A(H1N1) 2009 vaccines in preventing influenza in the United Kingdom

AU - Pebody, R.G.

AU - Andrews, Nick

AU - Fleming, D.M.

AU - McMenamin, J.

AU - Cottrell, S.

AU - Smyth, B.

AU - Durnall, H.

AU - Robertson, Chris

AU - Carman, W.

AU - Ellis, J.

AU - Sebastian-Pillai, P.

AU - Zambon, Maria

AU - Hearns, C.

AU - Moore, C.

AU - Thomas, D.R.

AU - Watson, J.M.

PY - 2013/3

Y1 - 2013/3

N2 - An analysis was undertaken to measure age-specific vaccine effectiveness (VE) of 2010/11 trivalent seasonal influenza vaccine (TIV) and monovalent 2009 pandemic influenza vaccine (PIV) administered in 2009/2010. The test-negative case-control study design was employed based on patients consulting primary care. Overall TIV effectiveness, adjusted for age and month, against confirmed influenza A(H1N1)pdm 2009 infection was 56% (95% CI 42–66); age-specificadjusted VE was 87% (95% CI 45–97) in <5-year-olds and 84% (95% CI 27–97) in 5- to 14-year-olds. Adjusted VE for PIV was only 28% (95% CI x6 to 51) overall and 72% (95% CI 15–91) in <5-year-olds. For confirmed influenza B infection, TIV effectiveness was 57% (95% CI 42–68) and in 5- to 14-year-olds 75% (95% CI 32–91). TIV provided moderate protection against the main circulating strains in 2010/2011, with higher protection in children. PIV administered during the previous season provided residual protection after 1 year, particularly in the <5 years age group.

AB - An analysis was undertaken to measure age-specific vaccine effectiveness (VE) of 2010/11 trivalent seasonal influenza vaccine (TIV) and monovalent 2009 pandemic influenza vaccine (PIV) administered in 2009/2010. The test-negative case-control study design was employed based on patients consulting primary care. Overall TIV effectiveness, adjusted for age and month, against confirmed influenza A(H1N1)pdm 2009 infection was 56% (95% CI 42–66); age-specificadjusted VE was 87% (95% CI 45–97) in <5-year-olds and 84% (95% CI 27–97) in 5- to 14-year-olds. Adjusted VE for PIV was only 28% (95% CI x6 to 51) overall and 72% (95% CI 15–91) in <5-year-olds. For confirmed influenza B infection, TIV effectiveness was 57% (95% CI 42–68) and in 5- to 14-year-olds 75% (95% CI 32–91). TIV provided moderate protection against the main circulating strains in 2010/2011, with higher protection in children. PIV administered during the previous season provided residual protection after 1 year, particularly in the <5 years age group.

KW - Influenza

KW - vaccine-preventable diseases

KW - influenza vaccines

KW - age-specific

KW - vaccine effectiveness

KW - pandemic

UR - http://www.scopus.com/inward/record.url?scp=84876951407&partnerID=8YFLogxK

U2 - 10.1017/S0950268812001148

DO - 10.1017/S0950268812001148

M3 - Article

SN - 0950-2688

VL - 141

SP - 620

EP - 630

JO - Epidemiology and Infection

JF - Epidemiology and Infection

IS - 3

ER -

Age-specific vaccine effectiveness of seasonal 2010/2011 and pandemic influenza A(H1N1) 2009 vaccines in preventing influenza in the United Kingdom

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this